Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 92437
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.92437
Unveiling expression patterns, mechanisms, and therapeutic opportunities of transmembrane protein 106C: From pan-cancers to hepatocellular carcinoma
Jian-Di Li, Rong-Quan He, Yi-Wu Dang, Zhi-Guang Huang, Dan-Dan Xiong, Lu Zhang, Xiu-Fang Du, Gang Chen
Jian-Di Li, Yi-Wu Dang, Zhi-Guang Huang, Dan-Dan Xiong, Lu Zhang, Xiu-Fang Du, Gang Chen, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Rong-Quan He, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Author contributions: Chen G, He RQ, and Dang YW designed the study, supervised the experiments, and polished the manuscript; Li JD collected the transcriptomic data, performed all computational biological analyses, and drafted the manuscript; Huang ZG and Xiong DD performed the cellular and xenograft experiments; Zhang L and Du XF contributed to the collection of clinical samples; All authors read and approved the final manuscript.
Supported by the National Natural Science Foundation of China, No. NSFC82160762, No. NSFC82460783; Natural Science Foundation of Guangxi, No. 2022GXNSFBA035657; and Innovation Project of Guangxi Graduate Education, No. JGY2023068, No. YCSW2023220.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University, No. 2021-KY-Guoji-054.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Laboratory Animal Ethics Committee of Guangxi Medical University.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The datasets analyzed in this study are available in the open access repositories in Supplementary Table 1. Further inquiries can be directed to the corresponding author.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gang Chen, PhD, Professor, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, No. 22 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. chengang@gxmu.edu.cn
Received: January 25, 2024
Revised: September 30, 2024
Accepted: November 22, 2024
Published online: February 15, 2025
Processing time: 358 Days and 14.7 Hours
Core Tip

Core Tip: Herein, we conducted the first study to investigate the expression implications, immune associations, and transcriptional regulatory mechanisms of transmembrane protein 106C (TMEM106C) across 34 cancer types, including liver hepatocellular carcinoma (LIHC). Our multicenter study represents the largest investigation to date of the expression pattern and biological functions of TMEM106C in LIHC. Of particular note, our study discovered the inhibitory effect of nitidine chloride on TMEM106C overexpression, which has not been reported previously.